ΚΩΝΣΤΑΝΤΙΝΟΣ ΚΟΣΜΑΣ ΕΙΔΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ - ΛΙΠΙΔΙΟΛΟΓΟΣ https://validator.w3.org/feed/docs/rss2.html Services Υπηρεσίες Scientific Activity Contact Επικοινωνία Biography Βιογραφικό Home Footer-New-en Header-en Header Footer-New Ο καλύτερος προγνωστικός δείκτης καρδιαγγειακού κινδύνου: ApoB έναντι LDL-C και non-HDL-C Angiopoietin-like Protein 3 (ANGPTL3) Targeting in the Management of Dyslipidemias Όροι Χρήσης Terms & Conditions Πολιτική Απορρήτου Privacy Policy Lipoprotein(a) and calcific aortic valve stenosis Lipid Profile and Management of Dyslipidemias in Pregnancy Novel RNA-based therapies in the management of dyslipidemias Role of aspirin in the primary prevention of cardiovascular disease in patients with hyperlipoproteinaemia(a) Biomarkers of insulin sensitivity-resistance Inclisiran – the preclinical discovery and development of a novel therapy for the treatment of atherosclerosis Αρχική Inclisiran – the preclinical discovery and development of a novel therapy for the treatment of atherosclerosis PCSK9 Targeting in the Management of Hypercholesterolaemia Insulin resistance and cardiovascular disease The Triglyceride–High-Density Lipoprotein Cholesterol (TG–HDL-C) Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular Disease Environmental Factors Modifying HDL Functionality High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease Dysfunctional high-density lipoprotein and atherogenesis Inheritance of high and low HDL – mechanisms and management HDL Functionality: An Emerging Concept in Clinical Lipidology Chest Pain in the Hospital Evidence-based decision-making to reduce ASCVD risk: what do the latest data for novel lipid-lowering therapies show? How can novel lipid-lowering therapies meet the needs of individuals at high risk of ASCVD? What do we understand about dyslipidemias and the role of atherogenic lipoproteins in ASCVD risk? Role of aspirin in the primary prevention of cardiovascular disease in patients with hyperlipoproteinaemia(a) Νεότερες RNA θεραπείες στην αντιμετώπιση των δυσλιπιδαιμιών Ο ρόλος του εικοσιπενταενοϊκού οξέος (EPA) στη μείωση του καρδιαγγειακού κινδύνου ApoB vs LDL-χοληστερόλη. Ποιος είναι ο καλύτερος προγνωστικός δείκτης πρόβλεψης καρδιαγγειακών συμβαμάτων; Biomarkers of insulin sensitivity-resistance PCSK9 Targeting in the Management of Hypercholesterolaemia Novel RNA-based therapies in the management of dyslipidemias Angiopoietin-like Protein 3 (ANGPTL3) Targeting in the Management of Dyslipidemias Lipid Profile and Management of Dyslipidemias in Pregnancy Footer Insulin resistance and cardiovascular disease Επιστημονική Δραστηριότητα